Single answer
Is Kiniksa Pharmaceuticals Ltd (KNSA) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
$1 invested is now $1.09 or 8.85%
(In 6 weeks 1 day 13 hours 6 minutes and 32 seconds .)
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Kiniksa Pharmaceuticals Ltd is $52.50, which is $7.54 (16.77%) above the current price today's price.
Low target: $50.00 | High target: $55.00
Latest analyst updates
Recent rating and price target changes for this stock.
Company snapshot
A quick overview of the business and its public profile.
Kiniksa Pharmaceuticals Ltd a biopharmaceutical company focuses on discovering acquiring developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide Its product candidates include ARCALYST an interleukin1alpha and interleukin1beta for the treatment of recurrent pericarditis which is an inflammatory cardiovascular disease Mavrilimumab a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis Vixarelimab a monoclonal antibody which is in Phase 2a clinical trial for the treatment of prurigo nodularis a chronic inflammatory skin condition and KPL404 a monoclonal antibody inhibitor of the CD40 CD154 interaction a Tcell costimulatory signal critical for Bcell maturation immunoglobulin class switching and type 1 immune response Kiniksa Pharmaceuticals Ltd was incorporated in 2015 and is based in Hamilton Bermuda
Website: https://www.kiniksa.com
Rates and inflation backdrop
US inflation for December 2025 was 0.31%. Over the last 12 months, inflation is 3.03%. The 10-year yield is 4.29 and is up 0.240 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.01. Cash flow to debt ratio: 10.58. Net profit margin: 6.01%. Inflation risk score: low (0.10/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Kiniksa Pharmaceuticals Ltd is $19.5M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for Kiniksa Pharmaceuticals Ltd 10 years ago, but if you had invested on 2018-05-24 when the price was $19.47, you would have made a profit of $25.49 per share or 130.92%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.